{
    "nctId": "NCT04754399",
    "briefTitle": "Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias",
    "officialTitle": "Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias",
    "overallStatus": "COMPLETED",
    "conditions": "Arthralgia, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Absolute change in Brief Pain Inventory (BPI) worst pain from baseline to week 15",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal according to standard clinical criteria OR receiving concomitant LHRH agonist therapy.\n* Taking aromatase inhibitor therapy (anastrozole, exemestane, or letrozole) for adjuvant treatment of breast cancer or for chemoprevention for at least 3 weeks and no more than 2 years at the time of enrollment.\n* Planning to take the same AI therapy for at least 15 weeks.\n* New or worsening joint pain and/or myalgias since starting the AI therapy.\n* Completion of surgery (mastectomy or lumpectomy/partial mastectomy) for treatment of breast cancer at least 3 months prior to enrollment.\n* The complete list of inclusion criteria is provided in the protocol.\n\nExclusion Criteria:\n\n* Metastatic breast cancer.\n* Planned surgery during the 15-week study period.\n* Clinically significant laboratory abnormalities.\n* Use of cannabidiol, THC, or marijuana (oral, inhaled, or topical) within the 6 weeks prior to enrollment.\n* History of or currently has suicidal ideation or attempted suicide.\n* History of seizure other than febrile seizures in childhood.\n* The complete list of exclusion criteria is provided in the protocol.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}